Sunshine Biopharma (SBFM) Gross Margin (2018 - 2026)

Sunshine Biopharma's Gross Margin history runs 9 years deep, the most recent figure standing at 26.96% for Q1 2026.

• Quarterly Gross Margin fell 371.0% year-over-year to 26.96% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32.98% (up 250.0% YoY) and the FY2025 annual result came in at 33.76%, up 316.0% from the prior year.
• Gross Margin was 26.96% for Q1 2026 at Sunshine Biopharma, down from 35.31% in the prior quarter.
• Across five years, Gross Margin topped out at 51.2% in Q1 2022 and bottomed at 25.33% in Q2 2024.
• A 5-year average of 36.11% and a median of 33.98% in 2024 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2023 — Gross Margin tumbled 1706 bps — and 2025, when it soared 1105 bps.
• Sunshine Biopharma's Gross Margin stood at 37.85% in 2022, then retreated by 12 bps to 33.44% in 2023, then retreated by 4 bps to 32.24% in 2024, then increased by 10 bps to 35.31% in 2025, then retreated by 24 bps to 26.96% in 2026.
• Business Quant data shows SBFM's Gross Margin at 26.96% in Q1 2026, 35.31% in Q4 2025, and 32.64% in Q3 2025.